Dr. Reddy's Para 4 application strategy for generic business received a severe setback when Reddy's lost the patent challenge in the case of Pfizer's drug Norvasc (amlodipine maleate), a drug indicated for the treatment of hypertension and angina.
Dr. Reddy's Para 4 application strategy for generic business received a severe setback. This was what a drug indicated for the treatment of hypertension and angina. Reddy's lost the patent challenge in the case of Pfizer's drug Norvasc (amlodipine maleate).